David Swope, MD
Neurology · New York, NYNPI 1538193800
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,880 of the $3,498 with a category attached, or 82.3%. AbbVie accounts for 83.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $2,899 and has fallen 96.3% since, to $107 in 2023.
Across 11 payments — averaging $318.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Abbott$243
- Boston Scientific$133
- Acorda Therapeutics, Inc$107
- Medtronic$77
- Sunovion Pharmaceuticals Inc.$19
Across 4 payments — averaging $18,449 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$52K
- Biogen$21K
What the payments were for
- Speaking & faculty fees$2,88082%
- Food & beverage$61818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $2,919 |
| Abbott | 3 | $243 |
| Boston Scientific | 3 | $133 |
| Acorda Therapeutics, Inc | 1 | $107 |
| Medtronic | 1 | $77 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$2,880
- Infinity DBS Pulse Generators$154
- INBRIJA$107
How this compares
$3,498 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tetrabenazine | 14 | $116,811 |
| RytaryCarbidopa/Levodopa | 92 | $100,441 |
| Rasagiline Mesylate | 355 | $53,633 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 783 | $27,401 |
| Entacapone | 58 | $20,098 |
| AmantadineAmantadine Hcl | 178 | $9,333 |
| Primidone | 223 | $4,928 |
| Pramipexole ErPramipexole Di-Hcl | 28 | $4,888 |
| Zonisamide | 139 | $4,314 |
| Donepezil Hcl | 277 | $2,498 |
| Propranolol Hcl | 111 | $1,895 |
| Midodrine Hcl | 11 | $1,606 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 28 | $1,557 |
| Baclofen | 43 | $1,318 |
| Selegiline Hcl | 16 | $966 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.